Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FP-025 multiple ascending dose and food-effect study in healthy adults
NL-OMON44633Active, not recruiting
- Sponsor
- Foresee Pharmaceuticals
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of aderamastat in asthma and chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Foresee Pharmaceuticals. Primary endpoint: Safety and tolerability of multiple oral ascending doses of FP-025. Started Jul 2017; status: active, not recruiting.
02
Drugs
aderamastat
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON44633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44633.